multiple dose studies [Design Issues]

posted by dshah  – India, 2024-03-08 18:36 (494 d 18:00 ago) – Posting: # 23895
Views: 3,284

Hello Loky do!

❝

❝ I have a solifenacin succinate/tamsulosin HCl bioequivalence study, I will perform a multiple-dose study for tamsulosin modified release for Europe, I'm a little confused about the planned washout for this study as there are no enough public assessment reports for the combination, should I take in account the solifenacin washout period also or to design on tamsulosin only is enough (i.e one-week washout between 2 periods from last dose)

❝

As this is FDC- both the drug needs to be analyzed and thus also consider Solifenacin for washout consideration.

Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
23,436 posts in 4,932 threads, 1,676 registered users;
47 visitors (0 registered, 47 guests [including 11 identified bots]).
Forum time: 13:37 CEST (Europe/Vienna)

You are rewarding a teacher poorly
if you remain always a pupil.    Friedrich Nietzsche

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5